Back to Search

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies


  • Protocol Number: 202206002
  • Principal Investigator: Uy, Geoffrey
  • Cancer Types: Leukemia, Myeloma, and Hematologic, Lymphoma

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Protocol Interventions